Structural-Based Rational Design of an Antagonist Peptide That Inhibits the Ribosome-Inactivating Activity of Ricin A Chain

被引:0
作者
Shuntao Wang
Jiannan Feng
Jianwei Guo
Yan Li
Yingxun Sun
Weisong Qin
Meiru Hu
Beifen Shen
机构
[1] Institute of Basic Medical Sciences,
[2] Institute of Basic Medical Sciences,undefined
来源
International Journal of Peptide Research and Therapeutics | 2005年 / 11卷
关键词
Antagonist peptide; luciferase protein synthesis inhibition assay; ricin A chain; rational design;
D O I
暂无
中图分类号
学科分类号
摘要
Previous studies of inhibitors of ricin A chain (RA) mainly focused on the analogues of adenine and ribosomal RNA (rRNA) substrates. In this paper, a novel antagonist peptide (named PT) was designed rationally based on the crystal structure of the complex RA–rRNA. Theoretical results had clearly revealed the blockage of PT in the RA–rRNA interaction. The competitive inhibition experiment indicated that PT could significantly inhibit the binding activity of RA with anti-RA antibody. In order to further prove the competitive effect of PT against RA, N-glycosidase antagonizing activity of PT in cell-free system was evaluated using luciferase protein synthesis inhibition assay. Consequent data demonstrated that, at a RA level (0.022 nM) giving 50% decrease of protein synthesis in the absence of the peptide, protein synthesis could be recovered by the peptide for up to 80% at a level of 0.1 microgram/ml. This study highlights the interest of computation-aided method in the design of novel peptides with the ability to block the deleterious biological effects of RA. In addition, the method of luciferase protein synthesis inhibition assay in cell-free system which should provide rapid, sensitive, selective, and quantitative assessment may be developed to evaluate the potential antagonizing activity of RA inhibitors.
引用
收藏
页码:211 / 218
页数:7
相关论文
共 79 条
[1]  
Amukele T. K.(2004)undefined Biochemistry 43 4913-4922
[2]  
Schramm V. L.(1999)undefined Proc. Natl. Acad. Sci. USA 96 3957-3962
[3]  
Baluna R.(1999)undefined Nature 400 841-847
[4]  
Rizo J.(2000)undefined J. Am. Chem. Soc 122 1609-1617
[5]  
Gordon B. E.(1996)undefined J. Am. Chem. Soc 118 3067-3068
[6]  
Ghetie V.(1998)undefined J. Toxicol. Toxin Rev 17 427-439
[7]  
Vitetta E. S.(2000)undefined J. Biol. Chem 275 4937-4942
[8]  
Ban N.(2004)undefined Anal. Biochem 330 119-122
[9]  
Nissen P.(2003)undefined Biotech. Lett 25 1671-1675
[10]  
Hansen J.(1999)undefined Curr. Opin. Immunol 11 570-578